H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Humacyte (HUMA – Research Report) today and set a price target of $15.00.
Vernon Bernardino has given his Buy rating due to a combination of factors surrounding Humacyte’s promising market position and product performance. The recent investor event highlighted the early market success of Symvess, an acellular tissue-engineered vessel, which has received full FDA approval for specific vascular applications. This approval, coupled with the positive reception from Value Analysis Committees at various hospitals, suggests a strong commercial launch is imminent.
Symvess has demonstrated superior performance compared to traditional prosthetic grafts and shows comparable results to autologous veins, as evidenced by clinical trials and real-world applications. The product’s ability to significantly reduce amputation and infection rates, along with its mechanical durability, positions it as a transformative solution in vascular trauma care. These compelling clinical outcomes and market readiness underpin Bernardino’s confidence in Humacyte’s growth potential, justifying the reiterated Buy rating and the $15 price target.
In another report released on March 10, TD Cowen also maintained a Buy rating on the stock with a $7.50 price target.